FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367300694> ?p ?o ?g. }

• W4367300694 endingPage "741" @default.
• W4367300694 startingPage "732" @default.
• W4367300694 abstract "Abstract Background Sexual dysfunction may indicate severe endocrine diseases. Recent research has suggested a link between hypothyroidism, low testosterone (T) levels, and erectile dysfunction (ED); however, the exact cause is unknown. Aim We sought to investigate possible beneficial effects of levothyroxine and T alone or in combination on ED in propylthiouracil (PTU)-induced hypothyroid rats. Methods Adult Wistar rats (n = 35) were divided into 5 groups: control, PTU-induced hypothyroidism, PTU + levothyroxine, PTU + Sustanon (a mixture of 4 types of T: propionate, phenylpropionate, isocaproate, and decanoate) and PTU + levothyroxine + Sustanon. PTU was given in drinking water for 6 weeks. Four weeks after PTU administration, levothyroxine (20 μg microgram kg/day, oral) and Sustanon (10 mg/kg/week, intramuscular) were given for 2 weeks. Serum levels of total T, triiodothyronine (T3), and thyroxine (T4) were determined. In vivo erectile response and in vitro relaxant responses were measured. Localization of neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS), and phosphodiesterase type 5 (PDE5) were determined using immunohistochemical analysis. The relative area of smooth muscle to collagen was measured using Masson trichrome staining. Outcomes Outcome variables included in vivo erectile function, in vitro relaxant and contractile responses of corpus cavernosum (CC) strips; protein localization of eNOS, nNOS, and PDE5; and smooth muscle content in penile tissue. Results The rat model of hypothyroidism showed a significant decline in serum levels of total T, T3, and T4. Levothyroxine increased T3 and T4 levels, whereas Sustanon normalized only total T levels. Combined treatment enhanced all hormone levels. Rats with hypothyroidism displayed the lowest erectile response (P &lt; 0.001 vs controls). Combined treatment returned reduced responses, while partial amelioration was observed after levothyroxine and Sustanon treatment alone. Acetylcholine (P &lt; 0.01 vs controls), electrical field stimulation (P &lt; 0.001 vs controls), and sildenafil-induced relaxant responses (P &lt; 0.05 vs controls) were decreased in the CC strips from hypothyroid rats. The combined treatment increased the reduction in relaxation responses. Levothyroxine and Sustanon restored decreases in eNOS and nNOS expression in the hypothyroid group. There was no significant difference in PDE5 expression among groups. Monotreatment partially enhanced reduced smooth muscle mass, while combined therapy completely recovered. Clinical Implications The combination of thyroid hormones and T is likely to be a therapeutic approach for treatment of hypothyroidism-induced ED in men. Strengths and Limitations Beneficial effects of levothyroxine and Sustanon treatment were shown in vitro and in vivo in PTU-induced hypothyroid rats. The main limitation of the study was the lack of measurement of androgen-sensitive organ weights and luteinizing hormone, follicle-stimulating hormone, and prolactin levels. Conclusion These findings demonstrate that neurogenic and endothelium-dependent relaxation responses are reduced by hypothyroidism, which is detrimental to T levels and erectile responses. Levothyroxine and Sustanon combination medication was able to counteract this effect." @default.
• W4367300694 created "2023-04-29" @default.
• W4367300694 creator A5007247398 @default.
• W4367300694 creator A5013759531 @default.
• W4367300694 creator A5020844161 @default.
• W4367300694 creator A5023087869 @default.
• W4367300694 creator A5036588525 @default.
• W4367300694 creator A5040358062 @default.
• W4367300694 creator A5041577160 @default.
• W4367300694 creator A5063355650 @default.
• W4367300694 creator A5066037765 @default.
• W4367300694 creator A5072348280 @default.
• W4367300694 creator A5084457457 @default.
• W4367300694 date "2023-04-27" @default.
• W4367300694 modified "2023-10-15" @default.
• W4367300694 title "Combined levothyroxine and testosterone treatment for restoring erectile dysfunction in propylthiouracil-induced hypothyroid rats" @default.
• W4367300694 cites W1054473502 @default.
• W4367300694 cites W1540260113 @default.
• W4367300694 cites W1562814494 @default.
• W4367300694 cites W1986415843 @default.
• W4367300694 cites W1990586673 @default.
• W4367300694 cites W2000457923 @default.
• W4367300694 cites W2005444336 @default.
• W4367300694 cites W2015383498 @default.
• W4367300694 cites W2027109764 @default.
• W4367300694 cites W2035452556 @default.
• W4367300694 cites W2043590202 @default.
• W4367300694 cites W2065955842 @default.
• W4367300694 cites W2067523787 @default.
• W4367300694 cites W2085879568 @default.
• W4367300694 cites W2093983507 @default.
• W4367300694 cites W2095714184 @default.
• W4367300694 cites W2100698636 @default.
• W4367300694 cites W2107937411 @default.
• W4367300694 cites W2109596022 @default.
• W4367300694 cites W2124968539 @default.
• W4367300694 cites W2125818234 @default.
• W4367300694 cites W2137635355 @default.
• W4367300694 cites W2138502501 @default.
• W4367300694 cites W2145707064 @default.
• W4367300694 cites W2159866427 @default.
• W4367300694 cites W2162768237 @default.
• W4367300694 cites W2163149690 @default.
• W4367300694 cites W2171664151 @default.
• W4367300694 cites W2295745898 @default.
• W4367300694 cites W2297358297 @default.
• W4367300694 cites W2402051345 @default.
• W4367300694 cites W2531023673 @default.
• W4367300694 cites W2578658596 @default.
• W4367300694 cites W2606053726 @default.
• W4367300694 cites W2769097588 @default.
• W4367300694 cites W2772857684 @default.
• W4367300694 cites W2784109312 @default.
• W4367300694 cites W2791924666 @default.
• W4367300694 cites W2883958953 @default.
• W4367300694 cites W2943586990 @default.
• W4367300694 cites W2944201481 @default.
• W4367300694 cites W2946664098 @default.
• W4367300694 cites W3040885956 @default.
• W4367300694 cites W3043585145 @default.
• W4367300694 cites W3134290936 @default.
• W4367300694 cites W3173198494 @default.
• W4367300694 cites W3184990006 @default.
• W4367300694 cites W4312194986 @default.
• W4367300694 cites W4312989949 @default.
• W4367300694 doi "https://doi.org/10.1093/jsxmed/qdad034" @default.
• W4367300694 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37105943" @default.
• W4367300694 hasPublicationYear "2023" @default.
• W4367300694 type Work @default.
• W4367300694 citedByCount "0" @default.
• W4367300694 crossrefType "journal-article" @default.
• W4367300694 hasAuthorship W4367300694A5007247398 @default.
• W4367300694 hasAuthorship W4367300694A5013759531 @default.
• W4367300694 hasAuthorship W4367300694A5020844161 @default.
• W4367300694 hasAuthorship W4367300694A5023087869 @default.
• W4367300694 hasAuthorship W4367300694A5036588525 @default.
• W4367300694 hasAuthorship W4367300694A5040358062 @default.
• W4367300694 hasAuthorship W4367300694A5041577160 @default.
• W4367300694 hasAuthorship W4367300694A5063355650 @default.
• W4367300694 hasAuthorship W4367300694A5066037765 @default.
• W4367300694 hasAuthorship W4367300694A5072348280 @default.
• W4367300694 hasAuthorship W4367300694A5084457457 @default.
• W4367300694 hasBestOaLocation W43673006941 @default.
• W4367300694 hasConcept C126322002 @default.
• W4367300694 hasConcept C134018914 @default.
• W4367300694 hasConcept C2775883008 @default.
• W4367300694 hasConcept C2775960720 @default.
• W4367300694 hasConcept C2777622882 @default.
• W4367300694 hasConcept C2778288131 @default.
• W4367300694 hasConcept C2778326061 @default.
• W4367300694 hasConcept C2779279991 @default.
• W4367300694 hasConcept C2779929075 @default.
• W4367300694 hasConcept C519581460 @default.
• W4367300694 hasConcept C71315377 @default.
• W4367300694 hasConcept C71924100 @default.
• W4367300694 hasConceptScore W4367300694C126322002 @default.
• W4367300694 hasConceptScore W4367300694C134018914 @default.
• W4367300694 hasConceptScore W4367300694C2775883008 @default.

• next